Reduction of worsening renal function by adding dapagliflozin to manage acute heart failure

ROAD-AHF - ROAD-AHF

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044342

Enrollment

100

Registered

2021-05-28

Start date

2021-05-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute heart failure

Interventions

Dapagliflozin 10mg during hospitalization conventional therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acute heart failure. at least one physical examination, edema or jugular vein distension

Exclusion criteria

Exclusion criteria: use of inotropic agents mechanical support

Design outcomes

Primary

Measure	Time frame
the rate of worsening renal function	—

Secondary

Measure	Time frame
amounts of furosemide at discharge	—

Countries

Japan

Contacts

Public ContactShodai Kawanami

Osaka Rosai Hospital cardiology

junnai-hisho@osakah.johas.go.jp072-252-3561

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026